FEED 最新10-Q变化
将 FEED 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-17 与上一份 10-Q · 2026-05-18
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +38 | −17 | ~13 | 5 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 4 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 3 |
| 风险因素 | 文字有新增/删除 | +12 | 0 | 0 | 1 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-17
Following the ENvue Merger, the Company has progressively consolidated certain functions and resources across the combined organization in order to reduce duplication and improve operating efficiency. This has included the sharing of personnel and technical resources across the Company’s two product…
Three Months Ended June 30, 2026, Compared to Three Months Ended June 30, 2025
Revenues. For the three months ended June 30, 2026, and 2025, our revenues were approximately $239 and $494, respectively, a decrease of approximately 51.6%, or $255, between the periods. The decrease was primarily attributable to a halt in production of our PainShield/UroShield products resulting f…
This decline was partially offset by growth in ENvue revenues, which increased by approximately 275%, from approximately $49 to approximately $184, driven by continued expansion of our installed hospital base and adoption of the ENvue Navigation Platform. We also continued to generate revenues throu…
For the three months ended June 30, 2026, the percentage of revenues attributable to our products was: 16% for PainShield and monthly kits, 2% for UroShield and monthly kits, 77% for ENvue systems and tubes and 5% for other products. For the three months ended June 30, 2025, the percentage of revenu…
相对上期删除的文字 · 来源:10-Q · 2026-05-18
Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025
Revenues. For the three months ended March 31, 2026, and 2025, our revenues were approximately $653 and $1,025, respectively, a decrease of approximately 36%, or $372, between the periods. The decrease was primarily attributable to the removal of PainShield Ultra from the market, partially offset by…
For the three months ended March 31, 2026, the percentage of revenues attributable to our products was: 82% for PainShield and monthly kits and 18% for ENvue system and tubes. For the three months ended March 31, 2025, the percentage of revenues attributable to our products was: 85 % for PainShield …
Gross Profit (Loss). For the three months ended March 31, 2026, and 2025, gross profit (loss) was approximately ($55) and $369, respectively, a decrease of approximately 115% or $424. Gross margin was also significantly impacted, declining primarily due to the removal of PainShield Ultra from the ma…
Gross profit as a percentage of revenues were approximately (11%) and 36% for the three months ended March 31, 2026, and 2025, respectively. The decrease in gross profit as a percentage of revenues is mainly due to the reasons described above.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-17
If we fail to comply with the continued listing requirements of Nasdaq, our Common Stock may be delisted and the price of our Common Stock and our ability to access the capital markets could be negatively impacted.
Our Common Stock is currently listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum stockholders’ equity of $2.5 million and a minimum closing bid price of $1.00 per share or risk delisting, which would have a material adverse…
On July 10, 2026, we received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that the Staff has determined that the closing bid price of our Common Stock has been below $1.00 per share for th…
On April 10, 2024, we received the Letter from the Staff of Nasdaq indicating that, based upon the closing bid price of our Common Stock for the 30 consecutive business days between February 27, 2024 and April 9, 2024, we did not meet the minimum bid price of $1.00 per share required for continued l…
On November 19, 2024, we received an additional deficiency notice from the Staff indicating that we no longer satisfied the $2.5 million stockholders’ equity requirement set forth in the Equity Rule for continued listing on Nasdaq. The Staff indicated that our non-compliance with the Equity Rule wou…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议